ABSTRACT
BACKGROUND: Nitrogen fertiliser is the major input and cost for wheat production, being required to support the development of the canopy to maximise yield and for the synthesis of the gluten proteins that are necessary for breadmaking. Consequently, current high-yielding cultivars require the use of nitrogen fertilisation levels above the yield optimum to achieve the grain protein content needed for breadmaking. This study aimed to reduce this requirement by identifying traits that allow the use of lower levels of nitrogen fertiliser to produce wheat for breadmaking. RESULTS: A range of commercial wheat genotypes (cultivars) were grown in multiple field trials (six sites over 3 years) in the UK with optimal (200 kg Ha-1 ) and suboptimal (150 kg Ha-1 ) application of nitrogen. Bulked grain samples from four sites per year were milled and white flours were baked using three types of breadmaking process. This identified five cultivars that consistently exhibited good breadmaking quality when grown with the lower nitrogen application. Chemical and biochemical analyses showed that the five cultivars were characterised by exhibiting grain protein deviation (GPD) and high dough elasticity. CONCLUSIONS: It is possible to develop novel types of wheat that exhibit good breadmaking quality by selecting for GPD and high dough strength. © 2023 The Authors. Journal of The Science of Food and Agriculture published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
Subject(s)
Grain Proteins , Triticum/chemistry , Nitrogen/metabolism , Fertilizers , Bread/analysis , FertilizationABSTRACT
The central nervous system is the source of all behaviors and emotions; it also mediates the individual's relationship with the environment. Consequently, when the central nervous system is disrupted by neurologic disease, there are frequently many concomitant emotional and behavioral disturbances, as well as conflicts with the environment and the people surrounding the patient. Patients are often unaware that these maladaptive interactions often determine the nature and quality of care that they receive from their caregivers. The aggressive or wandering brain-damaged patient often ends up in a secure facility, and the apathetic patient often becomes forgotten. Although psychopharmacologic agents can moderate some of the behavioral and emotional symptoms of brain damage, these medications have side effects such as sedation and falls, among others, and they often interfere with the metabolism of medications that patients are already taking. Behavior therapy is an excellent supplement to, if not alternative for, medications to control symptomatic behaviors associated with brain damage for the following reasons: 1) behavioral treatment is nonpharmacologic, and, therefore, there are no drug interactions or side effects in patients with neurologic illnesses; 2) behavioral treatments can be designed to treat specific symptoms, and, by mitigating them, improve the quality of life of the patient and the caregivers; 3) the success of behavioral treatments can usually be quantified as the target behaviors are pinpointed and measured before, during, and after the behavioral interventions; 4) behavioral treatments are usually cost effective, because they can be devised by psychologists, but administered by direct daily caregivers and family members; and 5) behavioral treatments administered by caregivers give the caregivers a sense of participation and control of the treatment. Reports of the effectiveness of behavioral treatments support their inclusion as an important complementary component in the care of individuals with neurologic disorders as well as the milieu of institutions that care for the brain damaged.
Subject(s)
Mental Disorders/psychology , Nervous System Diseases/psychology , Adult , Aphonia/psychology , Bipolar Disorder/etiology , Bipolar Disorder/psychology , Brain Injuries/complications , Brain Injuries/psychology , Cognition/physiology , Diagnosis, Differential , Female , Humans , Male , Mental Disorders/diagnosis , Middle Aged , Multiple Sclerosis/psychology , Nervous System Diseases/diagnosis , Parkinson Disease/complications , Parkinson Disease/psychology , Somatoform Disorders/psychologySubject(s)
Depressive Disorder/etiology , Depressive Disorder/psychology , Nervous System Diseases/complications , Nervous System Diseases/psychology , Basal Ganglia Diseases/complications , Basal Ganglia Diseases/psychology , Brain Diseases/complications , Brain Diseases/psychology , Humans , Mood Disorders/etiology , Mood Disorders/psychologyABSTRACT
In order to characterize the onset and evolution of early cognitive changes that accompany bilateral electroconvulsive therapy (ECT), the performance of 13 ECT-treated and 16 psychiatric control patients on a battery of neuropsychological tests administered daily was compared. These tests included: Digit Symbol, spokes, letter cancellation, and short-term memory tests. While both groups improved on all tests, performance of ECT patients vs. controls on letter cancellation tests diverged significantly (p < 0.005) after three ECTs. The authors speculate that this finding reflects an alteration in attentional processes caused by bilateral ECT.
